A 2021 study [86] analyzed transcriptomic data from a cohort of 718 patients from independent trials and 1654 bone marrow samples from eight clinical trials and concluded that combined VISTA + , CD11b + , and CD8 + cell scores can be used to assess the prognosis of MM and to guide immunotherapy stratification of MM patients. This evidence concerns the gene CD8A and Miyoshi myopathy.